Brokerages Set $30.00 Target Price for Aravive Inc (NASDAQ:ARAV)

Aravive Inc (NASDAQ:ARAV) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price target of $30.00 for the company and are expecting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aravive an industry rank of 58 out of 255 based on the ratings given to related companies.

ARAV has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price target (up from $18.00) on shares of Aravive in a report on Wednesday, November 20th. Wedbush upped their price target on shares of Aravive from $12.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 20th. Robert W. Baird raised shares of Aravive from a “neutral” rating to an “outperform” rating in a report on Monday. Piper Jaffray Companies reiterated an “overweight” rating and set a $31.00 target price (down previously from $36.00) on shares of Aravive in a research note on Tuesday. Finally, ValuEngine lowered shares of Aravive from a “sell” rating to a “strong sell” rating in a research note on Tuesday.

In other Aravive news, CEO Jay Shepard sold 4,004 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. Also, Director Srinivas Akkaraju bought 133,333 shares of the stock in a transaction on Monday, December 2nd. The shares were acquired at an average price of $11.30 per share, with a total value of $1,506,662.90. 39.80% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in ARAV. Renaissance Technologies LLC increased its stake in Aravive by 13.8% during the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after purchasing an additional 18,017 shares during the last quarter. Vanguard Group Inc. increased its stake in Aravive by 4.7% during the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after purchasing an additional 7,200 shares during the last quarter. BlackRock Inc. increased its stake in Aravive by 5.8% during the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after purchasing an additional 9,544 shares during the last quarter. Finally, Artal Group S.A. increased its stake in Aravive by 20.0% during the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after purchasing an additional 51,197 shares during the last quarter. Hedge funds and other institutional investors own 30.85% of the company’s stock.

ARAV traded up $0.46 during trading on Wednesday, hitting $11.99. The company had a trading volume of 514,595 shares, compared to its average volume of 120,097. The company has a market cap of $108.86 million, a PE ratio of -1.13 and a beta of 2.35. The business has a 50-day moving average of $7.44 and a 200-day moving average of $6.53. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.59 and a quick ratio of 7.59. Aravive has a 1-year low of $3.07 and a 1-year high of $15.62.

Aravive (NASDAQ:ARAV) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.04). Research analysts forecast that Aravive will post -1.78 earnings per share for the current year.

Aravive Company Profile

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Recommended Story: What is meant by holder of record?

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.